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Abstract
Ventilator associated pneumonia (VAP) is the leading cause of morbidity and mortality in intensive
care units. The incidence of VAP varies from 7% to 70% in different studies and the mortality rates
are 20–75% according to the study population. Aspiration of colonized pathogenic microorganisms
on the oropharynx and gastrointestinal tract is the main route for the development of VAP. On the
other hand, the major risk factor for VAP is intubation and the duration of mechanical ventilation.
Diagnosis remains difficult, and studies showed the importance of early initiation of appropriate
antibiotic for prognosis. VAP causes extra length of stay in hospital and intensive care units and
increases hospital cost. Consequently, infection control policies are more rational and will save
money.
Introduction
Nosocomial pneumonia (NP) is defined as parenchymal
lung infection, occurring after the first 48 hours of hospi-
tal admission [1]. It accounts for 13–18% of all hospital-
acquired infections, but leading cause of death from noso-
comial infections [2]. It is a major threat to patients
admitted intensive care units (ICU) and receiving
mechanical ventilation (MV). In the recent studies, it was
shown that ventilator associated pneumonia (VAP) was
the most common infectious complication among
patients admitted ICU [3,4]. It results in high mortality
and morbidity, prolonged lengths of hospitalisation, and
also increased cost of hospitalisation. The mortality rates
for VAP range from 20% to 75% according to the study
population [5-13]. The average excess cost of pneumonia
was estimated to be U.S.$1255 per patient in 1982 (14),
U.S.$2863 per patient in 1985 [15], and in a recent study
in 1999, it was >U.S.$40 000 per patient [16].
Despite the clinical experience and major advances in
diagnostic techniques and management, VAP remains a
significant problem for intensivists. In this review, epide-
miology, diagnosis and, mainly, infection control of VAP
were discussed.
Epidemiology
Incidence
In different studies, the incidence of VAP was reported dif-
ferent, depending on the definition, the type of hospital
or ICU, the population studied, and the type of rate calcu-
lated and varies from 7% to 70% [17-23]. In a large data-
base, 1-day point prevalence study, conducted in 1417
European ICUs, pneumonia accounted for 47% of noso-
comial infections [4]. In the National Nosocomial Infec-
tions Surveillance System (NNIS), NP accounted for 31%
of all nosocomial infections in ICU [24] and in another
NNIS data in medical ICUs, it was accounted for 27%
[25]. The recent studies reported the device-associated
incidence rate 13.2–51 per 1000 ventilator days
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[20,23,26,27]. Generally, the rates of VAP in surgical ICU
were higher than in medical ICUs, depending on the dif-
ferences in the patient population, surgical disorders, the
proportion of patients that needed MV and the duration
of ventilation. Kollef et al. [28] reported incidences of NP
of 21.6% in patients admitted to a cardiothoracic ICU,
14% in other surgical ICU, and 9.3% in a medical ICU.
Pathophsiology
NP may occur by four routes; haematogenous spread from
a distant focus of infection, contiguous spread, inhalation
of infectious aerosols and aspiration. Aspiration of the
pathogenic gram-positive and gram-negative bacteria, col-
onized on the oropharynx and gastrointestinal tract, is the
main route. The role of other routes is very rare [1].
Once microorganisms reach the distal lung, they multiply
and cause invasive disease. The host defence, including fil-
tration and humidification of air in the upper airways,
epiglottic and cough reflexes, ciliary transport by respira-
tory epithelium, phagocytes and opsonins in distal lung,
and systemic cell mediated and humoral immunity, pre-
vent bacterial invasion [29]. In ICU, the host defence of
patients are usually altered because of their underlying
diseases, and devices that are used. They can not cough
efficiently due to sedation or underlying disease. And also,
when they are intubated, the endotracheal tube holds the
vocal cords open and facilitates aspiration.
Risk factors
The most important risk factor for NP is tracheal intuba-
tion; associated with a 3 to 21 fold risk [30-33]. It
increases the risk by; 1) causing sinusitis and trauma to
nasopharynx (nasotracheal tube), 2) impairing swallow-
ing of secretions, 3) acting as a reservoir for bacterial pro-
liferation, 4) increasing bacterial adherence and
colonization of airways, 5) requiring the presence of a for-
eign body that traumatizes the oropharyngeal epithelium,
6) causing ischemia secondary to cuff pressure, 7) impair-
ing ciliary clearance and cough, 8) causing leakage of
secretions around the cuff, and 9) requiring suctioning to
remove secretions [34]. Microorganisms can adhere to the
surface of the endotracheal tube and some species exude
an exopolysaccharide that acts as a slime-like adhesive.
That microbial biofilm on the tube surface provides a res-
ervoir of microorganisms, and they are greatly resistant to
the action of antimicrobials and host defence [35]. Also,
the patient requiring MV exposes to other devices, such as
nebulizers, humidifiers, which can be the source of micro-
organisms.
The duration of MV increases the risk of infection. Cook et
al. [22] reported a cumulative increased risk of VAP with
time, with 3% per day in the first week of MV, 2% per day
in the second week, and 1% per day in the third week. In
other studies, similarly, it was shown that the risk of pneu-
monia increased by the duration of MV and the highest
risk was during the first 8–10 days [36-38]. The need for
reintubation, urgent intubation and documented massive
aspiration are also associated with high incidence of VAP
[1,21,29,39].
The effect of prior antibiotic therapy is still controversial.
Sirvent et al. [40] reported that a short course of cepha-
losporin prophylaxis was associated with a lower rate of
VAP in patients with structural coma. Also other investiga-
tors showed that antibiotics administered during the first
days, reduced the risk of early-onset ventilator associated
pneumonia [22,37]. However, prior antibiotic exposure
predisposes patients to subsequent colonization and
infection with resistant pathogens [28,41].
Nasogastric tubes impair the function of the gastro-
esophageal sphincter and increase the risk of maxillary
sinusitis, oropharyngeal colonization and reflux, all of
which may lead to migration of bacteria and pneumonia
[29,39]. Enteral nutrition given by nasogastric tube is also
associated with increased risk of VAP. Moreover, it may
predispose to VAP by elevating gastric pH, leading to gas-
tric colonization and increasing the risk of reflux and aspi-
ration by causing gastric distension [22,42,43]. Also
patient transportation was found risk factor for VAP by
facilitating the aspiration of contaminated secretions
from the upper airway and the ventilator circuits in the
supine position [44].
The other independent risk factors for VAP are shown in
Table 1[6,7,11,22,28,33,34,45]. Identifying these risk fac-
tors will guide to prevention measures of VAP.
Etiologic agents
The causative organisms vary according to the patients'
demographics in the ICU, methods of diagnosis, the dura-
tions of hospital and ICU stays, and the antibiotic policy.
Gram negative bacteria are the most common pathogens
cause VAP in several studies [7,17,44]. In NNIS data,
although the most frequent reported isolate was Staphylo-
coccus aureus (17%), 59% of all reported isolates were
gram-negative. The most common gram-negative species
were Pseudomonas aeruginosa (15.6%), Enterobacter species
(10.9%), and Klebsiella pneumoniae (7.0%) (24). In recent
years, gram-positive bacteria have become more common
in ICU and in the EPIC study, S. aureus accounted for 31%
of the 836 cases with identified microorganisms (46).
NNIS data from medical ICU, also, reported high percent-
age (20%) of S. aureus [25]. Polymicrobial infection rate
is usually high in VAP [12,17,47,48].
The duration of MV and the prior exposure to antimicro-
bials significantly influence the distribution patterns ofAnnals of Clinical Microbiology and Antimicrobials 2006, 5:7 http://www.ann-clinmicrob.com/content/5/1/7
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etiologic agents. In early onset VAP (<5 days), methicillin-
sensitive S. aureus, Streptococcus pneumoniae, and Haemo-
philus influenzae are the most common pathogens,
whereas methicillin-resistant S. aureus (MRSA), P. aerugi-
nosa, Acinetobacter baumannii and Stenotrophomonas mal-
tophilia are more frequent in late onset VAP (≥ 5 days)
[49,50]. Also, MRSA, P. aeruginosa, A. baumannii and the
other multi-resistant gram negative pathogens are the
most common pathogens in the patients expose to prior
antibiotic.
The other special factors that predispose patients to infec-
tion with specific microorganisms are summarized in
Table 2[29,51-56]. Determining risk factors for microor-
ganisms will help to select appropriate antimicrobial
treatment, that improves the outcome.
Diagnosis
The diagnosis of pneumonia in mechanically ventilated
patients is difficult, and still there is no "gold-standard"
diagnostic method. It is usually based on the combination
of clinical, radiological, and microbiological criteria
defined by Centers for Disease and Control (CDC) (Table
3). But these criteria have low sensitivity and specificity.
The systemic signs (fever, leukocytosis, etc.) of infection
can be seen by any condition in ICU (pulmonary edema,
pulmonary infarction, after surgery, trauma, devascular-
ized tissue, open wounds, etc.). Investigators reported that
the clinical diagnosis of VAP is associated 30–35% false-
negative and 20–25% false-positive results [57-59]. And
also, ICU patients do not always have systemic signs of
infection due to their underlying disease (chronic renal
failure, immunosuppresion, etc.). Radiological infiltra-
tion has limited value, mimicking by cardiogenic pulmo-
nary edema, noncardiogenic pulmonary edema, adult
respiratory distress syndrome (ARDS), atelectasis, pulmo-
nary contusion, which are not uncommon in ICU [29]. In
an autopsy-proven VAP study, Wunderink et al. [1]
reported that no radiographic sign had a diagnostic accu-
racy greater than 68%. The presence of air bronchograms
was the only sign that correlated well with pneumonia,
correctly predicting 64% of pneumonias in the entire
group. The upper respiratory tract of patients is colonized
with potential pulmonary pathogens a few hours after
intubation [48,61]. Consequently, isolation of pathogens
from tracheal secretions do not always indicate pulmo-
nary infection. But a positive Gram's stain may guide the
initial antibiotic therapy. However prior antibiotic and
corticosteroid therapy can reduce the sensitivity of this
technique [62,63].
Pugin et al. [64] proposed to combine the seven variables
(temperature, leukocytes, tracheal aspirate volume and
purulence of tracheal secretions, chest X-ray, oxygenation-
PaO2/FiO2- and semiquantitative culture of tracheal aspi-
rate) for the diagnosis of VAP, defined as clinical pulmo-
nary infection score (CPIS) (Table 4). The score varied
from 0 to 12 points and was reported that a CPIS of more
than six was associated with a sensitivity of 93% and a
specificity of 100% for the diagnosis of pneumonia. In a
post mortem study, Papazian and colleagues [65]
reported a high diagnostic accuracy of CPIS at a threshold
of 6 (72% sensitivity and 85% specificity). However, the
original scoring system has some limitations; that it
requires 24–48 hours for the results of tracheal aspirate
cultures, and also identifying pulmonary infiltrates pro-
gression depends on intensivist experience. Singh et al.
[66] used a modified CPIS (calculated at baseline from the
first five clinical variables, and CPIS at 72 hours was based
on all variables of the score) that antibiotics were stopped
in patients with a persistent low score (<6) after 3 days of
therapy, avoiding unnecessary use of antibiotics, and all
patients who discontinued the therapy improved. In a
recent study, Fartoukh et al. [67] reported that the modi-
fied CPIS does not perform better when the clinical suspi-
cion of pneumonia is high, so they proposed
Table 1: Risk factors for ventilator associated pneumonia
Host factors Intervention factors Other factos
Age ≥ 60 yr Duration of MV Season: fall, winter
Severity of illness Reintubation
Organ failure PEEP
Poor nutritional state or hypoalbuminemia Frequent ventilator circuit changes
Upper abdominal or thoracic surgery Nasogastric tube
ARDS Intracranial pressure monitoring
Chronic lung disease Paralytic agents, sedation
Neuromuscular disease H2 blockers ± antacids
Trauma, burns >4 units of blood products
Coma, depressed level of consciousness Supine head position
Large-volume aspiration Transport out of the ICU
Upper respiratory tract colonization
Gastric colonization and pH
SinusitisAnnals of Clinical Microbiology and Antimicrobials 2006, 5:7 http://www.ann-clinmicrob.com/content/5/1/7
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incorporating the results of specimens gram stain (by add-
ing two more points when gram stains were positive) to
modified CPIS to increase the sensitivity of the score and
the physicians' diagnostic accuracy.
Qualitative cultures of tracheal aspirate (TA) is not a spe-
cific diagnostic method because of the lower respiratory
tract colonization and a high percentage of false-positive
results [48,68]. However, investigators reported that
quantitative cultures of TA have equal diagnostic accuracy
to the other invasive techniques [69-73]. In a recent study,
quantitative cultures of TA were compared with plugged
telescoping catheter (PTC). The specificity of TA was sim-
ilar to PTC when a cut-off point of 106 cfu/mL or higher
was used, although the sensitivity of TA at ≥ 106 cfu/mL
was lower than PTC. But when a cut-off point of 105 cfu/
mL was used, the sensitivity of TA was not statistically dif-
ferent from that of PTC [74]. Although, quantitative cul-
tures of TA is non-invasive, inexpensive and a simple
method, it has some risks, that if the cut-off value ≥ 106
cfu/mL is used, sensitivity will be low and some patients
with VAP may not be identified or when the cut-off value
≥ 105 cfu/mL is used, unnecessary antibiotic treatment
will be given because of low specificity [75].
In the recent years, many investigators favour invasive
techniques for diagnosis of pneumonia (protected-speci-
men brush -PSB- or bronchoalveolar lavage-BAL-) that
may have more diagnostic accuracy [76-80]. In PSB, 0.001
mL of secretions are collected and the presence of >103
cfu/mL bacteria has 80–90% sensitivity and 95% specifi-
city for the diagnosis of VAP. In BAL, larger proportion of
lung can be sampled and the diagnostic threshold is >104
cfu/mL. The sensitivity and specificity of BAL are 86–
100% and 95–100%, respectively [76,81-83]. Heyland
and colleagues [84] proposed that PSB or BAL may
increase physician confidence in the diagnosis and man-
agement of VAP and allows for greater ability to limit or
discontinue antibiotic therapy. Also in this study, patients
who underwent bronchoscopy with PSB and BAL had a
lower mortality rate compared with patients who did not
undergo bronchoscopy. However, a recent meta-analysis
concluded that regular use of bronchoscopy for the diag-
nosis of VAP does not alter mortality, because it does not
directly affect the initial antibiotic prescription [85]. The
disadvantages of these invasive techniques are [71,86,87];
a) prior antibiotic use may decrease the sensitivity and
accuracy of these methods. However, in a recent study,
Souweine et al. [88] reported that if a current antibiotic
treatment prescribed for a prior infectious disease other
than VAP, the diagnostic accuracy of protected specimen
brush or bronchoalveolar lavage is not changed, b) these
techniques are based on quantitative culture and results of
these cultures require 24–48 hours, and, therefore miss
early cases, and also give no information about appropri-
ate initial antibiotic therapy, c) these invasive tests may
worsen the patient's status (cardiac arrhythmias, hypox-
emia, bleeding, etc.), d) increase the costs of caring, e) it
has not been proven that the use of these invasive tech-
niques lead to a decrease in patients' mortality.
The spread of microorganism to blood or pleural space is
<10%, so blood and pleural effusion cultures have low
sensitivity and specificity. Luna and colleagues [89] dem-
onstrated that the positive predictive value of blood cul-
tures to detect the etiologic microorganism was 73% and
the sensitivity of blood cultures was only 26%. They con-
Table 3: CDC criteria for ventilator associated pneumonia
Three or more of the following criteria:
Rectal temperature >38°C or <35.5°C
Blood leucocytosis (>10.103/mm3) and/or left shift or blood 
leukopenia (<3.103/mm3)
More than ten leukocytes in Gram stain of tracheal aspirate (in high 
power field)
Positive culture from endotracheal aspirate
AND
New, persistent, or progressive radiographical infiltrate
Table 2: Risk factors for spesific microorganisms
Microorganism Risk factor
H. influenzae, Moraxella catarhalis, S. pneumoniae Chronic obstructive pulmonary disease (COPD), early-onset VAP
P. aeruginosa, A. baumannii Corticosteroid therapy, malnutrition, lung disease (bronchiectasis, cystic fibrosis), late-onset VAP, 
prior antibiotic exposure
S. aureus Coma, head-trauma, neurosurgery, diabetes mellitus, chronic renal insufficiency, influenza
Anaerobes Aspiration
Legionella Chemotherapy, corticosteroid therapy, malignancy, renal insufficiency, neutropenia, 
contamination of (hospital) water system
Aspergillus Corticosteroid therapy, cytotoxic drugs, COPD
Candida albicans Immunosuppression, cytotoxic drugs, corticosteroid therapy, broad-spectrum antibiotics
Influenza Winter season, immunosuppression, chronic underlying disease
Respiratory syncytial virus Immunosuppression, chronic cardiac or pulmonary diseaseAnnals of Clinical Microbiology and Antimicrobials 2006, 5:7 http://www.ann-clinmicrob.com/content/5/1/7
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cluded that blood cultures in patients with VAP are useful
if there is suspicion of another probable infectious condi-
tion, but the isolation of a microorganism in the blood
does not confirm that microorganism as the pathogen
causing VAP. Therefore, two sets of blood samples for cul-
ture and tapping pleural effusions >10 mm should be per-
formed in patients suspected VAP [50].
In conclusion, microbiological testing should be always
performed to decide the appropriate initial empirical anti-
biotic therapy. Clinicians can choose optimal diagnostic
test for specific patients in their clinical setting.
Infection control
Because of longer duration of mechanical ventilation,
longer stay in the ICU, increased use of antibiotics, higher
costs for healthcare, and most importantly, increased
mortality, the prevention of VAP is the major priority. But,
despite the advances in the pathogenesis of VAP, intensiv-
ists still struggle with the prevention strategy.
Hand hygiene
Basic hygiene principles of infection control (hand wash-
ing/disinfection just before and after each patient contact,
the use of glove and sterile equipment) remain important
for the prevention of VAP. Healthcare workers (HCW) can
spread microorganisms from patient to patient by their
hands easily. Although HCWs realize the importance of
handwashing/disinfection, their compliance is still low
(25–40%) [90-92]. Especially their compliance rate is
lowest in activities that carried higher risk for transmis-
sion and in ICU. High workload decreases their compli-
ance [93]. Wrist watches, bangles, and other jewellery act
as reservoirs for organisms, and inhibit effective hand
cleaning [94]. Therefore, staff have to take off wrist watch
and jewellery to achieve effective hand cleaning. They
have to use gowns and gloves when appropriate and must
change and wash/disinfect their hands between patients
[95]. Bedside hand antiseptics (alcohol-based handrub
solution), easier access to sinks and availability of wash-
ing equipment, decrease in workload, communication
and education tools (posters) and feedback improve com-
pliance and decrease the cross-transmission of nosoco-
mial infection [90,96].
Ventilator equipment
The internal machinery of mechanical ventilators is not an
important risk factor for VAP. Therefore, using a filter
between the inspiratory phase circuit and the patient is
not necessary. Furthermore, the importance of filters on
the expiratory limb of the mechanical-ventilator circuit in
preventing cross comtamination has not known and
needs further investigation [34].
The devices used on the respiratory tract come into contact
with mucous membranes, therefore cleaning and high-
level disinfection (at 75°C for 30 minutes) of reusable
equipments are required [97]. Resuscitation bags, spirom-
eters, and oxygen analyzers must be cleaned and disin-
fected between patients to avoid cross-transmission [95].
In several studies, routine changing of the ventilator cir-
cuits is not recommended [26,98-104]. Replacement is
required when there is gross soilage and mechanical mal-
function [105]. The condensate fluid in the ventilator cir-
cuit, which contains high concentration of pathogenic
bacteria and a risk factor for VAP, has to be removed reg-
ularly [106]. And accidental drainage of condensate into
the patient's airway and contamination of caregivers dur-
ing ventilator disconnection or during disposal of con-
densate should be avoided. In-line devices with one-way
valves, put in place into disposable circuits and emptied
regularly, are recommended for collecting condensate
[75].
Table 4: Clinical pulmonary infection score
Temperature, °C ≥ 36.5 and ≤ 38.4 0 point
≥ 38.5 and ≤ 38.9 1 point
≥ 39.0 and ≤ 36.0 2 point
Blood leucocytosis, mm3 ≥ 4000 and ≤ 11 000 0 point
<4000 and >11 000 1 point
+band forms ≥ 500 + 1 point
Tracheal secretions <14+ of tracheal secretions 0 point
≥ 14+secretions 1 point
+purulent sputum +1 point
Oxygenation: PaO2/FiO2, mmHg >240 or ARDS 0 point
≤ 240 and no ARDS 2 point
Chest X-ray No infiltrate 0 point
Diffused, or patchy infiltrate 1 point
Localized infiltrate 2 point
Culture of tracheal aspirate (semi-quantitative: 0-1-2 or 3+) ≤ 1 or no growth 0 points
Pathogenic bacteria cultured >1+ 1 point
>1+ and same pathogenic bacteria seen in Gram stain 2 pointAnnals of Clinical Microbiology and Antimicrobials 2006, 5:7 http://www.ann-clinmicrob.com/content/5/1/7
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Humidification of the inspired air is an important care in
the ventilator management. Humidification may be
achieved by active humidifiers (bubble-through or wick)
or passive humidifiers (hygroscopic condenser-artificial
nose- or heat-moisture exchanger-HME-). In humidifica-
tion, formation of condensate in tubing and colonization
of this condensate with microorganisms is an important
risk factor for VAP. HME recycle heat and moisture that
reduces the condensate formation and also bacterial colo-
nization in the circuit. Moreover they have bacterial filtra-
tion characteristics [34,98]. They do not need to be
changed daily and can be used for at least 48 hours, some-
times for up to 1 week [107,108]. Also with other advan-
tages (reduced nurses workload, reduced financial cost,
and better safety), HMEs are favourable devices in many
ICUs. Indeed several investigators [109-112] reported
lower rates of VAP in HME groups than conventional
heated-water humidification systems, the effect of HME
on the prevention of VAP is still controversial and a recent
study showed no significant difference in VAP rates [113].
Furthermore, HMEs increase dead space and resistance to
breathing, cause airway occlusion, and more tenacious
secretions [34,98,104,111]. Additional studies are needed
to identify the benefits of HMEs on infection control of
VAP.
Nebulizers are used for medication or humidification of
air, and inserted into the inspiratory phase of the mechan-
ical ventilator circuit. They can be contaminated by con-
densate in the tube or by using contaminated solutions,
and inoculate infectious aerosol particles directly into the
lung parenchyma and can cause outbreaks in ICUs. Rec-
ommendations for the infection control of nebulizers are;
a) filling immediately before use, b) using sterile water
and drugs, c) never refilling the liquid to be nebulised, d)
cleaning and disinfecting the receptacle daily, d) using
sterile water for rinsing and allowing to dry, e) using
patient-specific large-volume nebulizers, f) using patient
specific mask, mouthpiece, connecting pieces and medi-
cine cups [34,114].
Suctioning the secretions in the trachea is another
approach to VAP prevention. Two types of tracheal suc-
tion catheters are used on ventilated patients; the open,
single-use catheters and the closed, multiple-use catheters.
In single-use system, HCWs have to use sterile solutions
during rinsing these catheters and have to care aseptic
technique when suctioning endotracheal secretions. In
closed suctioning systems, secretions can be suctioned
without removal of mechanical ventilation support. This
may cause less hypoxia, hypotension and arrhythmias,
and also less environmental contamination [115,116].
However similar VAP rates with closed and open system
were suggested in the earlier trials [115,117], Combes and
colleagues [116] reported a 3.5 times greater risk of VAP
in open suctioning system than closed suctioning system
in a recent study. Indeed, closed suction catheter is an
extension of the ventilator circuit, daily change of this
catheter is not necessary for infection control, and in one
study no significant difference in VAP rate was reported
when daily changes were compared with no routine
changes, that may decrease the costs [118]. The use of
closed suction system is recommended as part of a VAP
prevention program [104].
Non-invasive ventilation
The relationship between the use of invasive devices and
nosocomial pneumonia directed the investigators to use
noninvasive ventilation to reduce the VAP rates. In several
studies, lower risk of VAP, with less antibiotic use, with a
shorter length of ICU stay, and with lower mortality were
reported in the use of non-invasive ventilation [119-123].
Therefore, care can be taken to use non-invasive mechan-
ical ventilation more often, and to reduce the frequency of
tracheal intubation.
Endotracheal tubes
Endotracheal tube alters host defences, impairs mechani-
cal clearance from the respiratory tract, causes local
trauma and inflammation, and allows pooling of secre-
tions around the cuff. The pressure of the endotracheal
tube-cuff should be sufficient to prevent the leakage of
colonized subglottic secretions into the lower airway [37].
Also, continuous or intermittent suctioning of oropharyn-
geal and upper respiratory tract secretions above endotra-
cheal cuffs can prevent aspiration. Endotracheal tubes
with a separate dorsal lumen above the cuff, designed to
suction the subglottic secretions continuously, were
found able to decrease the rates of early-onset VAP
[124,125]. However, in another randomised trial, no ben-
efit with continous subglottic suction on the overall VAP
frequency was found [126]. It can reduce but not elimi-
nate the volume of fluid aspirated into the lungs. The lack
of effect on prevention of late-onset pneumonia and the
high cost of these tubes restrict the usage of them.
Microbial biofilm on the endotracheal tube surface is a
reservoir for the pathogens and prevent the microorgan-
isms from the action of antibiotics [35]. Adair and col-
leagues [127] proposed that high concentrations of
antibiotic on the endotracheal luminal surface, achieved
either by nebuliser or endotracheal surface modification,
would be expected to prevent biofilm formation on the
endotracheal tube and may have a role in reducing the
incidence of VAP, also minimising patient exposure to
systemic antibiotics.
Nasotracheal intubation increases the risk of nosocomial
sinusitis, that may predispose VAP by the aspiration of
infected secretions from nasal sinuses [128,129]. There-Annals of Clinical Microbiology and Antimicrobials 2006, 5:7 http://www.ann-clinmicrob.com/content/5/1/7
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fore, endotracheal intubation should be preferred to
decrease the risk of VAP.
Nasotracheal tube and enteral nutrition
As nasotracheal intubation, nasogastric tube can cause
orophanryngeal colonization and nosocomial sinusitis.
By impairing the function of the upper oesophagus
sphincter, it may facilitate the reflux of bacteria from the
gut. As a result, it increases the risk of VAP [130,131]. In a
randomized study, gastroesophageal reflux and micro-
aspiration of gastric contents to the lower airways were
not influenced by the size of the nasogastric tube. Because
of their potential complications (tracheal malposition by
coiling and clogging) and high cost, the small-bore
nasogastric tubes are not routinely recommended for the
prevention of VAP [132].
Poor nutritional state and hypoalbuminemia contribute
the development of VAP. For this reason, early initiation
of enteral nutrition may have preventive effect in mechan-
ically ventilated patients. Moreover, it helps to maintain
the gastrointestinal epithelium and reduces the need for
stress-bleeding prophylaxis. However, because of using
nasogastric tubes and alkalinization of the stomach con-
tents by these feeds; gastric colonization, gastrooesopha-
geal reflux, aspiration and pneumonia might be
promoted [29]. In a recent study, postpyloric enteral
access placement improved tube-feeding tolerance and
reduced the rates of VAP [133]. Heyland et al. [134] used
acidified feeds in critically ill patients and demonstrated a
dramatic reduction in bacterial growth from aspirates of
stomach contents and a lower rate of gram-negative bacte-
rial growth in tracheal secretions in patients receiving
acidified feeds, but not a significant reduction in nosoco-
mial pneumonia. They cannot be used in patients with
active gastro-intestinal bleeding, acidemia, or renal fail-
ure. Furthermore, it was a small size study and further
research on the effect of prevention is needed, before it is
used in practice.
Selective digestive decontamination and oral care
In the recent years, selective decontamination of the diges-
tive tract (SDD) is one of the most extensively studied pre-
vention strategy in VAP. In SDD, topical non-absorbed
antimicrobials (usually combining polymyxin, aminogly-
coside and amphotericin B) are used to prevent gastroin-
testinal colonisation by pathogenic microorganisms. It
selectively eradicates the potential pathogenic microor-
ganisms (gram-negative aerobic intestinal bacteria, S.
aureus and fungi) and does not affect anaerobic flora, as
elimination of anaerobic flora leads to increased coloniza-
tion with gram-negative aerobic flora. Although some
investigators used only topical antibiotics applied to the
oropharynx and through a nasogastric tube, many of
them added systemic therapy with a broad spectrum (e.g.
cefotaxime) during the first few days, to prevent early
infections with S. pneumoniae, H. influenzae and S. aureus
[29]. In a recent meta-analysis that searched 33 rand-
omized controlled trials published from 1984 to 1996,
significant reductions in the incidence of respiratory tract
infections (65%) and in total mortality (20%) were deter-
mined [135]. Also in this meta-analysis and in the other
recent prospective, randomized studies, it was mentioned
that using only topical antibiotics reduced respiratory
infections, but did not influence the survival [135-137].
The threat of SDD is to lead the selection and overgrowth
of antibiotic resistant microorganisms. In a recent study
from the Netherlands, where the incidence of MRSA and
vancomycin resistant enterococcus (VRE) are very low, a
reduction in the frequency of colonization with resistant
gram-negative bacteria and no effect on the acquisition of
MRSA were reported (138). But the studies from the ICUs
where MRSA was endemic, increased incidence of MRSA
was reported (139,140). Therefore, in ICUs with high
incidence of multi-resistant microorganisms, SDD cannot
be used. On the other hand, in trauma and surgical
patients, SDD seems more effective than in medical
patients, may be due to less colonisation [141]. In conclu-
sion the routine use of SDD in ICUs is not recommended,
it should be decided according to the patient population
studied and the characteristic of ICU.
In addition, the colonization of the oral cavity with path-
ogens is important risk factor for the develoment of VAP,
it is unclear if oral care with chlorhexidine reduces VAP.
Also the concern over a chlorhexidine-related increase in
colonization of gram negative bacteria should be consid-
ered [142].
Body position and drugs
Semirecumbent position (45°) prevents aspiration and
the passage of bacteria into the airways, and should be
preferred in ICU patients, if there is no contraindication
[143].
"Kinetic Beds" or Continous Lateral Rotational Therapy
(CLRT) turn continuously and slowly and change the
patient's position. Investigators believe that it helps the
drainage of pulmonary secretions. However, these beds
are so expensive and their effectiveness are not demon-
strated. So, the routine use of these beds is not recom-
mended [97]. Also, chest physiotherapy, to improve the
clearance of secretions, for the prevention of VAP is not
recommended because of its lack of proven benefits and
the associated risks (e.g., arterial oxygen desaturation)
[105,144].
Stress ulcer prophylaxis is proposed to be a risk factor due
to the alkalinization of gastric content. The effect of stress
ulcer prophylaxis with H2-antagonists or antacids on VAPAnnals of Clinical Microbiology and Antimicrobials 2006, 5:7 http://www.ann-clinmicrob.com/content/5/1/7
Page 8 of 11
(page number not for citation purposes)
is still controversial. In some studies [145,146], the use of
sucralfate was associated with a decreased incidence of
VAP, however the other reports did not support this
[147,148]. Also, H2-antagonists are more efficient for
anti-ulcer prophylaxis than the sucralfate [148]. There-
fore, the choice of agent for prophylaxis should be done
according to the patient and cost-effectiveness.
To reduce the aspiration of oropharyngeal contents, over
use of sedatives should be avoided. Kress et al. [149]
reported that for reducing over use of sedatives, daily
interruption of sedative-drug infusions until the patients
were awake decreased the duration of mechanical ventila-
tion and the length of stay in the ICU.
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